Philadelphia, United States
Exegenesis Bio is a pioneering clinical stage global gene therapy company, founded in 2019, with operations in Philadelphia, Boston, and China. Their mission is encapsulated in their slogan: "We are reimagining ways to develop & manufacture gene therapies. Our mission is to improve efficacy, safety & access."
The company’s advanced pipeline leverages proprietary technologies, including novel capsids, promoters, and innovative protein engineering designs. Key clinical programs include a Type I Spinal Muscular Atrophy (SMA) gene therapy in China and a neurovascular Age-related Macular Degeneration (AMD) therapy in the USA. To support these initiatives, Exegenesis Bio has constructed state-of-the-art manufacturing facilities featuring 500L and 2,000L disposable bioreactors for viral vectors.
Since its inception, Exegenesis Bio has successfully raised over $150 million, notably securing Series B funding on February 2, 2021, from prominent investors including K2VC, Kaitai Capital, and Temasek Holdings. The company employs over 200 experts worldwide, positioning itself as a formidable player in biotechnology and healthcare.
